EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials

Yingjie Qiu iD, Yan Han, Beibei Guo iD

Statistics in Medicine · 2026

DOI: 10.1002/sim.70357 ↗

At a glance

Journal article in Statistics in Medicine, 2026. Written by Yingjie Qiu and 2 co-authors. Institution: Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: Immunotherapy, Biomarkers, Clinical Trials as Topic. Cited 2 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, Indiana Clinical and Translational Sciences Institute, National Cancer Institute.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

In immunotherapy, both the dose and the schedule of drug administration can significantly influence therapeutic effects by modulating immune system activation. Incorporating immune response measures into clinical trial designs offers an opportunity to enhance decision‐making by leveraging their close association with therapeutic efficacy and toxicity. Motivated by settings where biomarker data indicate improved efficacy in biomarker‐positive patients, we propose a dose–schedule optimization strategy tailored to each biomarker‐defined subgroup, based on elicited utility functions that capture risk‐benefit tradeoffs. We introduce a joint modeling framework that simultaneously evaluates immune response, toxicity, and efficacy, enabling information sharing across outcome types and patient subgroups. Our approach utilizes parsimonious yet flexible models designed specifically to address challenges due to small sample sizes commonly encountered in early‐phase trials. Simulation studies demonstrate that the proposed design achieves desirable operating characteristics and effectively informs dose–schedule optimization.

Subjects

MeSH terms (MEDLINE)

ImmunotherapyBiomarkersClinical Trials as TopicHumansComputer SimulationBayes TheoremDrug Administration ScheduleResearch DesignModels, StatisticalDose-Response Relationship, Drug

Author keywords

Bayesian adaptive designbiomarkerimmunotherapyoptimal treatment regimephase I/II trialrisk‐benefit tradeoffsubgroups

Substances

Biomarkers

Authors and institutions

  • Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, Indiana, USA.
  • Department of Experimental Statistics, Louisiana State University, Baton Rouge, Louisiana, USA.

ORCID profiles: Yingjie Qiu, Beibei Guo

Funding

  • NCI NIH HHS
  • Indiana Clinical and Translational Sciences Institute
  • National Cancer Institute

Cite

APA

Qiu, Y., Han, Y., & Guo, B. (2026). A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70357

Vancouver

Qiu Y, Han Y, Guo B. A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials. Statistics in Medicine. 2026. doi:10.1002/sim.70357

BibTeX
@article{Qiu2026,
  author = {Qiu, Yingjie and Han, Yan and Guo, Beibei},
  title = {A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials},
  journal = {Statistics in Medicine},
  year = {2026},
  doi = {10.1002/sim.70357}
}
Start for free →